SlideShare a Scribd company logo
Do you know what you are talking about?
Differences in the TTO valuation of (currently) experienced
and non-experienced health profiles
Cubi-Molla, Patricia1; Devlin, Nancy1; Shah, Koonal1; Herdman, Mike1
Contact: Patricia Cubi-Molla • Email: pcubi-molla@ohe.org • Tel: +44 (0)20 7747 8868 • Mobile: 07766912502
BACKGROUND
Literature supports the idea that health states are usually
evaluated more positively when they are experienced than
when they are imagined (De Wit et al., 2000). This
discrepancy is the basis of the debate about using public- or
patient-based preferences. The choice of the former or the
latter may lead to significantly different value sets, and it is
not clear whether it is desirable for health state values to be
influenced by the prior experiences of respondents
Acknowledgements
The authors want to thank Dr. Elly A. Stolk for her
feedback on a preliminary version of the project
References
De Wit, G. A., Busschbach, J. J. & De Charro, F. T., 2000. Sensitivity and perspective in the valuation of
health status: whose values count?. Health Economics, 9(2), pp. 109-126
Dolan, P., 1997. Modeling Valuations for EuroQol Health States. Medical Care, Volume 35, pp. 1095-1108
METHODS
Nancy will be in the “experience-based” (EB) group associated
to a health state H if she reported H as her own health state in
[1], and H is one of the profiles she valued via TTO and VAS in [2]
Koonal will be in the “non-experience-based” (NEB) group
associated to H if H is one of the profiles he valued via TTO and
VAS in [2], but he did not report H as his own health state in [1]
Methods:
(1) Probit regression models controlling for X = (sex, age, age
square, if parents, if employed, and several social group and
education), to analyse the characteristics of the EB group
(2) ANOVA and Mean comparison (t-tests) of TTO, VAS and VAS
adjusted values by group, to look for significant differences
in the values between EB and NEB groups
(3) Different OLS regression models to establish the effect of
currently experiencing the health profile to be valued on the
observed TTO value, controlling for X
(4) Pearson’s or Fischer’s tests to explore differences in the
ranking position of each profile with respect to death, for EB
and NEB groups
(5) Replicate the Dolan N3 model for generating the tariffs, but
adding being in the EB group as an explanatory factor.
(6) Compare EQ-VAS from "own health state" vs. raw VAS value
from "hypothetical health state" (test if difference = 0)
RESULTS
DISCUSSION / CONCLUSION
• In general, EB values for TTO and VAS seem to be slightly higher
than the NEB values. However this is not observed for all the
selected profiles. It is also not clear if VAS and TTO follow the
same pattern, that is, if being currently experiencing a health
state affects similarly the VAS and TTO valuation of it
• We cannot find evidence supporting the application of different
weights to the EQ-5D dimensions for creating the TTO values.
• Caveat: small subsamples!
• Work in progress: larger datasets (pooled across countries?)
could be used to check if the results are robust to alternative
definitions of the NEB group; extend the analysis to alternative
definitions of “experience”.
• From (1) we can suggest that the differences (if any) between
the values assigned by the EB and NEB can only be attributed to
the fact that the rater is currently living in the same health state
as the profile she is valuing (e.g. rather than to observable
characteristics of the sample)
DEFINING “EXPERIENCE”
Imagine we ask Nancy to value a health state H. The idea that
Nancy has “experience in H” has several interpretations:
i. Personal experience (“feeling”)
a. Nancy is currently living in H
b. Nancy lived in the past in H
ii. Vicarious experience (“knowledge”)
a. Affective: Nancy knows someone very closely attached to her
who lived/lives in H (e.g. relative, informal carer)
b. Non-affective: Nancy knows someone distant to her who
lived/lives in H (e.g. health professionals, formal carers)
1 Office of Health Economics, London
What we
study here
DATA MVH Study database (Dolan, 1997) n= 2,958
Every respondent:
[1] described their own health state using the EQ-5D-3L descriptive
system and EQ-VAS score
[2] ranked 12 EQ-5D-3L hypothetical profiles, together with “11111”,
“Unconscious” and “Immediate death”, and valued them by using:
- EQ-VAS (Raw or later on Adjusted by anchoring them between
“11111” and “Death”)
- TTO protocol (Adjusted to [-1,1], with death = 0)
AIM
Explore how currently experiencing a health state H may
affect the TTO or VAS valuation of H
EB group NEB group Total
Profile n % % Cum. n n
21111 57 22.89 22.89 1,103 1,160
11112 51 20.48 43.37 1,138 1,189
11121 51 20.48 63.85 1,132 1,183
11211 22 8.84 72.69 1,177 1,199
11122 19 7.63 80.32 711 730
12111 18 7.23 87.55 1,167 1,185
21222 14 5.62 93.17 713 727
22222 7 2.81 95.98 751 758
Other 10 4.02 100.00 27,355 27,365
Total 249 100 35,247 35,496
Other profiles (frequency): 11131 (2), 22112 (2), 33212 (2),
12211 (1), 21232 (1), 22233 (1), 32211 (1)
Experience- and non-experience- based groups
(1) None of the demographic and socio-economic characteristics in X has been found to be
significant (at 5% level) to explain the group composition. Therefore we conclude that the EB
group associated to a particular EQ profile has randomly selected among those facing the
task of valuing that profile following the TTO protocol
(2) Cells show the differences in means by group
(mean value for experience-based minus mean
value for non-experience-based). Blank cell = no
evidence to reject equal means
range [-1,1] [0,100] [-31.3,1] [0,100] [0,100]
profile TTO VAS VAS_adj Death Full Health
21111 + 0.33*
11112 + 0.04* + 2.91*
11121 + 0.10*** + 4.17** + 0.05***
11211
11122 + 6.00** + 0.08** - 1.24*
12111 + 0.93***
21222 + 8.70** + 0.16*** - 4.71*** + 0.72***
22222 + 0.38*** + 0.08* - 7.26*** n/a
(3) Only significant coefficients for the dummy
being in EB group or not for TTO and VAS
adjusted are shown. Age and age squared are
also found to be significant in most of the
regressions (this is not observed in other
variables in X). Additional OLS regressions have
been run interacting being in EB group or not
with dummies for three age categories, but the
results have not changed significantly
profile TTO [95% Conf. Int] VAS adjust [95% Conf. Int]
21111 -0.059** -0.117 -0.002 -0.066* -0.145 0.012
11121 0.087** 0.011 0.163 0.062* -0.010 0.133
22222 0.352** 0.008 0.695
(4) Differences are not found to be significant for
the position of the selected profiles with respect
to death, either for VAS or for TTO
(5) The Dolan N3 regression model has been applied.
The coefficient is found to be negative (-0.012) but
not significant (z=-0.49). Its inclusion or running
separate regressions for EB and NEB groups hardly
affect the coefficients of the remaining variables
(6) No evidence
that both scores
are significantly
different or one
greater than the
other along all
the profiles
11112
11112
22222
11122
21111
21222
11112
21111
11121
1121111121
1121112111
11122
21222
22222
21111
21111
22222
21222
21222
11211
21111
22222
11112
11122
22222
11122
21111
21111
11122
11121
21111
22222
21222
12111
12111
11121
21222
21111
11112
2111121111
21111
21222
21111
11121
21222
11122
11121
11121
21111
21111
11122
11122
21111
11121
21111
21111
11112
11112
21222
11122
21111
11211
21222
21111
12111
11112
11112
1121121222
12111
21111
22222
11211
11112
12111
11122
11121
11211
11122
21111
11211
11122
11112
11112
21111
2111111122
11121
11211
21111
11121
11211
11112
11121
21111
11121
12111
11121
11121
1121111112
11112
11112
11121
11112
11121
1112111112
11112
11112
1211111211
11121
21111
11121
11211
12111
21111
21222
11121
11112
12111
21222
11112
21111
21111
11121
11121
21111
11112
11122
11112
11121
11112
11112
21111
21111
2111111112
1112221111
2111111122
11122
11112
11112
1111211112
21111
11121
12111
11112
12111
11112
11211
11122
11121
11112
11121
11112
21111
21111
21222
11112
12111
11121
11112
1112112111
21111
11121
11112
11211
11112
11112
2111121111
11112
2111111121
11112
2111111121
12111
11112
11112
11121
21111
11211
1112121111
11211
12111
12111
21111
11121
1112111112
11121
21111
11121
21111
21111
21111
11121
21111
11112
12111
21111
11112
11121
11121
11211
21111
11112
11121
11121
11112
11121
11121
11121
11211
21111
11211
11112
11121
11211
11121
11121
11121
11112
11122
11121
0
.2.4.6.8
1
VASforself-reportedhealthprofile
0 .2 .4 .6 .8 1
VAS for hypothetical health profile
Adjusted VAS values by individual in EB group
22222
21222
11122
21111
11211
12111
11112
11121
0
.2.4.6.8
1
VASforself-reportedhealthprofile
0 .2 .4 .6 .8 1
VAS for hypothetical health profile
Average adjusted VAS by selected EQ profiles - EB group range [0,100] [-31.3,1]
profile N VAS Corr VAS_adj Corr
ALL 248 0.34 0.55
21111 57 - 5.39** 0.07 - 0.092** 0.74
11112 51 + 4.75** 0.21 + 0.067** 0.35
11121 51 0.13 0.01
11211 22 0.34 0.11
11122 19 + 6.00** 0.14 0.34
12111 18 - 5.06* -0.05 - 0.056* 0.07
21222 14 + 8.70** 0.21 0.19
22222 7 0.18 0.28

More Related Content

What's hot

Bowen PhD Final Seminar 2016
Bowen PhD Final Seminar 2016Bowen PhD Final Seminar 2016
Bowen PhD Final Seminar 2016
Daniel Bowen
 
Difference between QI, EBP & Research
Difference between QI, EBP & ResearchDifference between QI, EBP & Research
Difference between QI, EBP & ResearchYvonne Wesley
 
RiWC_PARA_A140 assessing vocational rehabilitation engagement of people with ...
RiWC_PARA_A140 assessing vocational rehabilitation engagement of people with ...RiWC_PARA_A140 assessing vocational rehabilitation engagement of people with ...
RiWC_PARA_A140 assessing vocational rehabilitation engagement of people with ...
Marco Muscroft
 
Biostatistics and its importance to Biologist
Biostatistics and its importance to BiologistBiostatistics and its importance to Biologist
Biostatistics and its importance to Biologist
Walid Nabil Saleh, DBA, MIBA, B.sc of Elec.Eng.
 
Patient Comprehension of FDA-Approved Medication Guides
Patient Comprehension of FDA-Approved Medication GuidesPatient Comprehension of FDA-Approved Medication Guides
Patient Comprehension of FDA-Approved Medication GuidesAllison Russell
 
HLT 362V Education Organization - snaptutorial.com
HLT 362V  Education Organization - snaptutorial.comHLT 362V  Education Organization - snaptutorial.com
HLT 362V Education Organization - snaptutorial.com
donaldzs199
 
History 35700 european socialism spring 2021essay 1 – the anar
History 35700 european socialism spring 2021essay 1 – the anarHistory 35700 european socialism spring 2021essay 1 – the anar
History 35700 european socialism spring 2021essay 1 – the anar
modi11
 
Hlt 362 v Exceptional Education / snaptutorial.com
Hlt 362 v Exceptional Education / snaptutorial.comHlt 362 v Exceptional Education / snaptutorial.com
Hlt 362 v Exceptional Education / snaptutorial.com
Baileya62
 
ORS in non-clinical sample
ORS in non-clinical sampleORS in non-clinical sample
ORS in non-clinical sample
Barry Duncan
 
Hlt 362 v Effective Communication / snaptutorial.com
Hlt 362 v  Effective Communication / snaptutorial.comHlt 362 v  Effective Communication / snaptutorial.com
Hlt 362 v Effective Communication / snaptutorial.com
HarrisGeorg26
 
Christy Starr Denman Poster
Christy Starr Denman PosterChristy Starr Denman Poster
Christy Starr Denman PosterChristy Starr
 
The Interpretation of Evidence Based Practice -Crimson Publishers
The Interpretation of Evidence Based Practice -Crimson PublishersThe Interpretation of Evidence Based Practice -Crimson Publishers
The Interpretation of Evidence Based Practice -Crimson Publishers
Crimsonpublishers-Rehabilitation
 
Value of transferability and efficiency in HTA
Value of transferability and efficiency in HTAValue of transferability and efficiency in HTA
Value of transferability and efficiency in HTA
Office of Health Economics
 
Clinical significance
Clinical significanceClinical significance
Clinical significance
SergeyPolyakov20
 
Introduction of Biostatistics
Introduction of BiostatisticsIntroduction of Biostatistics
Introduction of Biostatistics
Sir Parashurambhau College, Pune
 
HLT 362V Inspiring Innovation/tutorialrank.com
 HLT 362V Inspiring Innovation/tutorialrank.com  HLT 362V Inspiring Innovation/tutorialrank.com
HLT 362V Inspiring Innovation/tutorialrank.com
jonhson133
 
WTP-2015-Obesity
WTP-2015-ObesityWTP-2015-Obesity
WTP-2015-ObesityReza Alavi
 
Hlt 362 v Believe Possibilities / snaptutorial.com
Hlt 362 v  Believe Possibilities / snaptutorial.comHlt 362 v  Believe Possibilities / snaptutorial.com
Hlt 362 v Believe Possibilities / snaptutorial.com
StokesCope25
 
Kabboord comobidity 2016 THE FINAL version
Kabboord comobidity 2016 THE FINAL versionKabboord comobidity 2016 THE FINAL version
Kabboord comobidity 2016 THE FINAL versionAnouk Kabboord
 

What's hot (20)

Bowen PhD Final Seminar 2016
Bowen PhD Final Seminar 2016Bowen PhD Final Seminar 2016
Bowen PhD Final Seminar 2016
 
Chapter 019
Chapter 019Chapter 019
Chapter 019
 
Difference between QI, EBP & Research
Difference between QI, EBP & ResearchDifference between QI, EBP & Research
Difference between QI, EBP & Research
 
RiWC_PARA_A140 assessing vocational rehabilitation engagement of people with ...
RiWC_PARA_A140 assessing vocational rehabilitation engagement of people with ...RiWC_PARA_A140 assessing vocational rehabilitation engagement of people with ...
RiWC_PARA_A140 assessing vocational rehabilitation engagement of people with ...
 
Biostatistics and its importance to Biologist
Biostatistics and its importance to BiologistBiostatistics and its importance to Biologist
Biostatistics and its importance to Biologist
 
Patient Comprehension of FDA-Approved Medication Guides
Patient Comprehension of FDA-Approved Medication GuidesPatient Comprehension of FDA-Approved Medication Guides
Patient Comprehension of FDA-Approved Medication Guides
 
HLT 362V Education Organization - snaptutorial.com
HLT 362V  Education Organization - snaptutorial.comHLT 362V  Education Organization - snaptutorial.com
HLT 362V Education Organization - snaptutorial.com
 
History 35700 european socialism spring 2021essay 1 – the anar
History 35700 european socialism spring 2021essay 1 – the anarHistory 35700 european socialism spring 2021essay 1 – the anar
History 35700 european socialism spring 2021essay 1 – the anar
 
Hlt 362 v Exceptional Education / snaptutorial.com
Hlt 362 v Exceptional Education / snaptutorial.comHlt 362 v Exceptional Education / snaptutorial.com
Hlt 362 v Exceptional Education / snaptutorial.com
 
ORS in non-clinical sample
ORS in non-clinical sampleORS in non-clinical sample
ORS in non-clinical sample
 
Hlt 362 v Effective Communication / snaptutorial.com
Hlt 362 v  Effective Communication / snaptutorial.comHlt 362 v  Effective Communication / snaptutorial.com
Hlt 362 v Effective Communication / snaptutorial.com
 
Christy Starr Denman Poster
Christy Starr Denman PosterChristy Starr Denman Poster
Christy Starr Denman Poster
 
The Interpretation of Evidence Based Practice -Crimson Publishers
The Interpretation of Evidence Based Practice -Crimson PublishersThe Interpretation of Evidence Based Practice -Crimson Publishers
The Interpretation of Evidence Based Practice -Crimson Publishers
 
Value of transferability and efficiency in HTA
Value of transferability and efficiency in HTAValue of transferability and efficiency in HTA
Value of transferability and efficiency in HTA
 
Clinical significance
Clinical significanceClinical significance
Clinical significance
 
Introduction of Biostatistics
Introduction of BiostatisticsIntroduction of Biostatistics
Introduction of Biostatistics
 
HLT 362V Inspiring Innovation/tutorialrank.com
 HLT 362V Inspiring Innovation/tutorialrank.com  HLT 362V Inspiring Innovation/tutorialrank.com
HLT 362V Inspiring Innovation/tutorialrank.com
 
WTP-2015-Obesity
WTP-2015-ObesityWTP-2015-Obesity
WTP-2015-Obesity
 
Hlt 362 v Believe Possibilities / snaptutorial.com
Hlt 362 v  Believe Possibilities / snaptutorial.comHlt 362 v  Believe Possibilities / snaptutorial.com
Hlt 362 v Believe Possibilities / snaptutorial.com
 
Kabboord comobidity 2016 THE FINAL version
Kabboord comobidity 2016 THE FINAL versionKabboord comobidity 2016 THE FINAL version
Kabboord comobidity 2016 THE FINAL version
 

Viewers also liked

A Comparison of Three EQ-5D Value sets
A Comparison of Three EQ-5D Value setsA Comparison of Three EQ-5D Value sets
A Comparison of Three EQ-5D Value sets
Office of Health Economics
 
A new method for valuing quality of life: Direct elicitation of personal util...
A new method for valuing quality of life: Direct elicitation of personal util...A new method for valuing quality of life: Direct elicitation of personal util...
A new method for valuing quality of life: Direct elicitation of personal util...
Office of Health Economics
 
ISPOR poster - direct elicitation 280415
ISPOR poster - direct elicitation 280415ISPOR poster - direct elicitation 280415
ISPOR poster - direct elicitation 280415
Office of Health Economics
 
Devlin mcda philadelphia ispor 150515
Devlin  mcda philadelphia ispor 150515 Devlin  mcda philadelphia ispor 150515
Devlin mcda philadelphia ispor 150515
Office of Health Economics
 
ISPOR poster ri lwcp 140515
ISPOR poster   ri lwcp  140515ISPOR poster   ri lwcp  140515
ISPOR poster ri lwcp 140515
Office of Health Economics
 
Adrian Towse Presentation - Modelling value of early access, 19 May 2015
Adrian Towse Presentation - Modelling value of early access, 19 May 2015Adrian Towse Presentation - Modelling value of early access, 19 May 2015
Adrian Towse Presentation - Modelling value of early access, 19 May 2015
Office of Health Economics
 
Differential Pricing of Medicines in Europe:  Implications for Access, Innova...
Differential Pricing of Medicines in Europe:  Implications for Access, Innova...Differential Pricing of Medicines in Europe:  Implications for Access, Innova...
Differential Pricing of Medicines in Europe:  Implications for Access, Innova...
Office of Health Economics
 
Anchoring Vignettes: Identifying response bias and DIF in self assessed health
Anchoring Vignettes: Identifying response bias and DIF in self assessed healthAnchoring Vignettes: Identifying response bias and DIF in self assessed health
Anchoring Vignettes: Identifying response bias and DIF in self assessed health
Office of Health Economics
 
Can we really compare and aggregate PRO data between people and setting
Can we really compare and aggregate PRO data  between people and settingCan we really compare and aggregate PRO data  between people and setting
Can we really compare and aggregate PRO data between people and setting
Office of Health Economics
 
Is balancing value demonstration for payers and patient interests a feasible ...
Is balancing value demonstration for payers and patient interests a feasible ...Is balancing value demonstration for payers and patient interests a feasible ...
Is balancing value demonstration for payers and patient interests a feasible ...
Office of Health Economics
 
Modelling the Impact of Reform to the Cancer Drugs Fund
Modelling the Impact of Reform to the Cancer Drugs FundModelling the Impact of Reform to the Cancer Drugs Fund
Modelling the Impact of Reform to the Cancer Drugs Fund
Office of Health Economics
 
Adrian Towse Presentation - Affordability
Adrian Towse Presentation - Affordability Adrian Towse Presentation - Affordability
Adrian Towse Presentation - Affordability
Office of Health Economics
 
An Introduction Patient Reported Outcome Measures (PROMS)
An Introduction Patient Reported Outcome Measures (PROMS)An Introduction Patient Reported Outcome Measures (PROMS)
An Introduction Patient Reported Outcome Measures (PROMS)
Keith Meadows
 
HATi Toyko 2016 - Building Efficient Healthcare Systems Through Integrated He...
HATi Toyko 2016 - Building Efficient Healthcare Systems Through Integrated He...HATi Toyko 2016 - Building Efficient Healthcare Systems Through Integrated He...
HATi Toyko 2016 - Building Efficient Healthcare Systems Through Integrated He...
Office of Health Economics
 

Viewers also liked (14)

A Comparison of Three EQ-5D Value sets
A Comparison of Three EQ-5D Value setsA Comparison of Three EQ-5D Value sets
A Comparison of Three EQ-5D Value sets
 
A new method for valuing quality of life: Direct elicitation of personal util...
A new method for valuing quality of life: Direct elicitation of personal util...A new method for valuing quality of life: Direct elicitation of personal util...
A new method for valuing quality of life: Direct elicitation of personal util...
 
ISPOR poster - direct elicitation 280415
ISPOR poster - direct elicitation 280415ISPOR poster - direct elicitation 280415
ISPOR poster - direct elicitation 280415
 
Devlin mcda philadelphia ispor 150515
Devlin  mcda philadelphia ispor 150515 Devlin  mcda philadelphia ispor 150515
Devlin mcda philadelphia ispor 150515
 
ISPOR poster ri lwcp 140515
ISPOR poster   ri lwcp  140515ISPOR poster   ri lwcp  140515
ISPOR poster ri lwcp 140515
 
Adrian Towse Presentation - Modelling value of early access, 19 May 2015
Adrian Towse Presentation - Modelling value of early access, 19 May 2015Adrian Towse Presentation - Modelling value of early access, 19 May 2015
Adrian Towse Presentation - Modelling value of early access, 19 May 2015
 
Differential Pricing of Medicines in Europe:  Implications for Access, Innova...
Differential Pricing of Medicines in Europe:  Implications for Access, Innova...Differential Pricing of Medicines in Europe:  Implications for Access, Innova...
Differential Pricing of Medicines in Europe:  Implications for Access, Innova...
 
Anchoring Vignettes: Identifying response bias and DIF in self assessed health
Anchoring Vignettes: Identifying response bias and DIF in self assessed healthAnchoring Vignettes: Identifying response bias and DIF in self assessed health
Anchoring Vignettes: Identifying response bias and DIF in self assessed health
 
Can we really compare and aggregate PRO data between people and setting
Can we really compare and aggregate PRO data  between people and settingCan we really compare and aggregate PRO data  between people and setting
Can we really compare and aggregate PRO data between people and setting
 
Is balancing value demonstration for payers and patient interests a feasible ...
Is balancing value demonstration for payers and patient interests a feasible ...Is balancing value demonstration for payers and patient interests a feasible ...
Is balancing value demonstration for payers and patient interests a feasible ...
 
Modelling the Impact of Reform to the Cancer Drugs Fund
Modelling the Impact of Reform to the Cancer Drugs FundModelling the Impact of Reform to the Cancer Drugs Fund
Modelling the Impact of Reform to the Cancer Drugs Fund
 
Adrian Towse Presentation - Affordability
Adrian Towse Presentation - Affordability Adrian Towse Presentation - Affordability
Adrian Towse Presentation - Affordability
 
An Introduction Patient Reported Outcome Measures (PROMS)
An Introduction Patient Reported Outcome Measures (PROMS)An Introduction Patient Reported Outcome Measures (PROMS)
An Introduction Patient Reported Outcome Measures (PROMS)
 
HATi Toyko 2016 - Building Efficient Healthcare Systems Through Integrated He...
HATi Toyko 2016 - Building Efficient Healthcare Systems Through Integrated He...HATi Toyko 2016 - Building Efficient Healthcare Systems Through Integrated He...
HATi Toyko 2016 - Building Efficient Healthcare Systems Through Integrated He...
 

Similar to OHE at PROMs Conference Sheffield 2016: Presentations and Posters

Bowen & Neill (2013) Adventure Therapy Meta-Analysis Presentation
Bowen & Neill (2013) Adventure Therapy Meta-Analysis PresentationBowen & Neill (2013) Adventure Therapy Meta-Analysis Presentation
Bowen & Neill (2013) Adventure Therapy Meta-Analysis Presentation
Daniel Bowen
 
Nfhk2011 mika kivimaki_turku2011
Nfhk2011 mika kivimaki_turku2011Nfhk2011 mika kivimaki_turku2011
Nfhk2011 mika kivimaki_turku2011
NFHK2011
 
BUSI 230Project 1 InstructionsBased on Larson & Farber sectio.docx
BUSI 230Project 1 InstructionsBased on Larson & Farber sectio.docxBUSI 230Project 1 InstructionsBased on Larson & Farber sectio.docx
BUSI 230Project 1 InstructionsBased on Larson & Farber sectio.docx
RAHUL126667
 
Ispor poster appropriate_comparator_health_state_in_tto_studies_kks_oct2014
Ispor poster appropriate_comparator_health_state_in_tto_studies_kks_oct2014Ispor poster appropriate_comparator_health_state_in_tto_studies_kks_oct2014
Ispor poster appropriate_comparator_health_state_in_tto_studies_kks_oct2014
Office of Health Economics
 
ohipprotocol.docx
ohipprotocol.docxohipprotocol.docx
ohipprotocol.docx
NinaAlionkaMendozaYa
 
Impacts of a Cash Plus Intervention on Gender Attitudes Among Tanzanian Adole...
Impacts of a Cash Plus Intervention on Gender Attitudes Among Tanzanian Adole...Impacts of a Cash Plus Intervention on Gender Attitudes Among Tanzanian Adole...
Impacts of a Cash Plus Intervention on Gender Attitudes Among Tanzanian Adole...
UNICEF Office of Research - Innocenti
 
Dementia Research in UoW CARE
Dementia Research in UoW CAREDementia Research in UoW CARE
Dementia Research in UoW CARE
Lucy Roberts
 
Cadth 2015 e3 eq5 d
Cadth 2015 e3  eq5 dCadth 2015 e3  eq5 d
Cadth 2015 e3 eq5 d
CADTH Symposium
 
HLEG thematic workshop on "Multidimensional Subjective Well-being", Andrew Clark
HLEG thematic workshop on "Multidimensional Subjective Well-being", Andrew ClarkHLEG thematic workshop on "Multidimensional Subjective Well-being", Andrew Clark
HLEG thematic workshop on "Multidimensional Subjective Well-being", Andrew Clark
StatsCommunications
 
SURE Poster 2014 Raluca Iancu and Liat Levita.potx
SURE Poster 2014 Raluca Iancu and Liat Levita.potxSURE Poster 2014 Raluca Iancu and Liat Levita.potx
SURE Poster 2014 Raluca Iancu and Liat Levita.potxRaluca Iancu
 
Badilla_VOPPT revised.pptx
Badilla_VOPPT revised.pptxBadilla_VOPPT revised.pptx
Badilla_VOPPT revised.pptx
AngeloMelgar5
 
Identify the Topic you Selected in the First Line of your Posting.docx
Identify the Topic you Selected in the First Line of your Posting.docxIdentify the Topic you Selected in the First Line of your Posting.docx
Identify the Topic you Selected in the First Line of your Posting.docx
wilcockiris
 
Research metholodogy report
Research metholodogy reportResearch metholodogy report
Research metholodogy report
Harjas Singh
 
Journal of Vocational Behavior 85 (2014) 361–373 Contents .docx
Journal of Vocational Behavior 85 (2014) 361–373 Contents .docxJournal of Vocational Behavior 85 (2014) 361–373 Contents .docx
Journal of Vocational Behavior 85 (2014) 361–373 Contents .docx
LaticiaGrissomzz
 
Everyday Discrimination, Gender Differences in Major Lifetime Discrimination,...
Everyday Discrimination, Gender Differences in Major Lifetime Discrimination,...Everyday Discrimination, Gender Differences in Major Lifetime Discrimination,...
Everyday Discrimination, Gender Differences in Major Lifetime Discrimination,...
Wayne State University College of Liberal Arts and Sciences
 
1000 Minds Poster
1000 Minds Poster1000 Minds Poster
1000 Minds Poster
Amy Livingstone
 
Glymour aaai
Glymour aaaiGlymour aaai
Glymour aaai
mglymour
 
Re-thinking the Concept of Experienced-based Values
Re-thinking the Concept of Experienced-based ValuesRe-thinking the Concept of Experienced-based Values
Re-thinking the Concept of Experienced-based Values
Office of Health Economics
 

Similar to OHE at PROMs Conference Sheffield 2016: Presentations and Posters (20)

Bowen & Neill (2013) Adventure Therapy Meta-Analysis Presentation
Bowen & Neill (2013) Adventure Therapy Meta-Analysis PresentationBowen & Neill (2013) Adventure Therapy Meta-Analysis Presentation
Bowen & Neill (2013) Adventure Therapy Meta-Analysis Presentation
 
Nfhk2011 mika kivimaki_turku2011
Nfhk2011 mika kivimaki_turku2011Nfhk2011 mika kivimaki_turku2011
Nfhk2011 mika kivimaki_turku2011
 
BUSI 230Project 1 InstructionsBased on Larson & Farber sectio.docx
BUSI 230Project 1 InstructionsBased on Larson & Farber sectio.docxBUSI 230Project 1 InstructionsBased on Larson & Farber sectio.docx
BUSI 230Project 1 InstructionsBased on Larson & Farber sectio.docx
 
Ispor poster appropriate_comparator_health_state_in_tto_studies_kks_oct2014
Ispor poster appropriate_comparator_health_state_in_tto_studies_kks_oct2014Ispor poster appropriate_comparator_health_state_in_tto_studies_kks_oct2014
Ispor poster appropriate_comparator_health_state_in_tto_studies_kks_oct2014
 
ohipprotocol.docx
ohipprotocol.docxohipprotocol.docx
ohipprotocol.docx
 
Dissertation
DissertationDissertation
Dissertation
 
Impacts of a Cash Plus Intervention on Gender Attitudes Among Tanzanian Adole...
Impacts of a Cash Plus Intervention on Gender Attitudes Among Tanzanian Adole...Impacts of a Cash Plus Intervention on Gender Attitudes Among Tanzanian Adole...
Impacts of a Cash Plus Intervention on Gender Attitudes Among Tanzanian Adole...
 
Dementia Research in UoW CARE
Dementia Research in UoW CAREDementia Research in UoW CARE
Dementia Research in UoW CARE
 
Cadth 2015 e3 eq5 d
Cadth 2015 e3  eq5 dCadth 2015 e3  eq5 d
Cadth 2015 e3 eq5 d
 
HLEG thematic workshop on "Multidimensional Subjective Well-being", Andrew Clark
HLEG thematic workshop on "Multidimensional Subjective Well-being", Andrew ClarkHLEG thematic workshop on "Multidimensional Subjective Well-being", Andrew Clark
HLEG thematic workshop on "Multidimensional Subjective Well-being", Andrew Clark
 
SURE Poster 2014 Raluca Iancu and Liat Levita.potx
SURE Poster 2014 Raluca Iancu and Liat Levita.potxSURE Poster 2014 Raluca Iancu and Liat Levita.potx
SURE Poster 2014 Raluca Iancu and Liat Levita.potx
 
Badilla_VOPPT revised.pptx
Badilla_VOPPT revised.pptxBadilla_VOPPT revised.pptx
Badilla_VOPPT revised.pptx
 
Identify the Topic you Selected in the First Line of your Posting.docx
Identify the Topic you Selected in the First Line of your Posting.docxIdentify the Topic you Selected in the First Line of your Posting.docx
Identify the Topic you Selected in the First Line of your Posting.docx
 
Research metholodogy report
Research metholodogy reportResearch metholodogy report
Research metholodogy report
 
Journal of Vocational Behavior 85 (2014) 361–373 Contents .docx
Journal of Vocational Behavior 85 (2014) 361–373 Contents .docxJournal of Vocational Behavior 85 (2014) 361–373 Contents .docx
Journal of Vocational Behavior 85 (2014) 361–373 Contents .docx
 
Everyday Discrimination, Gender Differences in Major Lifetime Discrimination,...
Everyday Discrimination, Gender Differences in Major Lifetime Discrimination,...Everyday Discrimination, Gender Differences in Major Lifetime Discrimination,...
Everyday Discrimination, Gender Differences in Major Lifetime Discrimination,...
 
1000 Minds Poster
1000 Minds Poster1000 Minds Poster
1000 Minds Poster
 
Glymour aaai
Glymour aaaiGlymour aaai
Glymour aaai
 
Re-thinking the Concept of Experienced-based Values
Re-thinking the Concept of Experienced-based ValuesRe-thinking the Concept of Experienced-based Values
Re-thinking the Concept of Experienced-based Values
 
Robert Kaestner
Robert KaestnerRobert Kaestner
Robert Kaestner
 

More from Office of Health Economics

Annual lecture
Annual lecture Annual lecture
Devlin ispor 2020 issues panel 20.05.20
Devlin ispor 2020 issues panel 20.05.20 Devlin ispor 2020 issues panel 20.05.20
Devlin ispor 2020 issues panel 20.05.20
Office of Health Economics
 
Towse 2020 antimicrobials melbourne final
Towse 2020 antimicrobials melbourne finalTowse 2020 antimicrobials melbourne final
Towse 2020 antimicrobials melbourne final
Office of Health Economics
 
Towse cgd price transparency seminar
Towse cgd price transparency seminarTowse cgd price transparency seminar
Towse cgd price transparency seminar
Office of Health Economics
 
OHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
OHE presents at G20 AMR-R&D meeting in Paris - Adrian TowseOHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
OHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
Office of Health Economics
 
Pricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian TowsePricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian Towse
Office of Health Economics
 
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...
% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...
Office of Health Economics
 
The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...
Office of Health Economics
 
ISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money isISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money is
Office of Health Economics
 
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Office of Health Economics
 
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
 IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY? IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
Office of Health Economics
 
Ispor 2019 poster - Patricia Cubi-Molla
Ispor 2019 poster - Patricia Cubi-MollaIspor 2019 poster - Patricia Cubi-Molla
Ispor 2019 poster - Patricia Cubi-Molla
Office of Health Economics
 
Understanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to peopleUnderstanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to people
Office of Health Economics
 
Novel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of lifeNovel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of life
Office of Health Economics
 
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Office of Health Economics
 
HTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMRHTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMR
Office of Health Economics
 
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Office of Health Economics
 
Pay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in EnglandPay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in England
Office of Health Economics
 
Real option value drugs: is it really an option?
Real option value drugs: is it really an option?Real option value drugs: is it really an option?
Real option value drugs: is it really an option?
Office of Health Economics
 
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
Office of Health Economics
 

More from Office of Health Economics (20)

Annual lecture
Annual lecture Annual lecture
Annual lecture
 
Devlin ispor 2020 issues panel 20.05.20
Devlin ispor 2020 issues panel 20.05.20 Devlin ispor 2020 issues panel 20.05.20
Devlin ispor 2020 issues panel 20.05.20
 
Towse 2020 antimicrobials melbourne final
Towse 2020 antimicrobials melbourne finalTowse 2020 antimicrobials melbourne final
Towse 2020 antimicrobials melbourne final
 
Towse cgd price transparency seminar
Towse cgd price transparency seminarTowse cgd price transparency seminar
Towse cgd price transparency seminar
 
OHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
OHE presents at G20 AMR-R&D meeting in Paris - Adrian TowseOHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
OHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
 
Pricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian TowsePricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian Towse
 
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...
% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...
 
The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...
 
ISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money isISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money is
 
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
 
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
 IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY? IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
 
Ispor 2019 poster - Patricia Cubi-Molla
Ispor 2019 poster - Patricia Cubi-MollaIspor 2019 poster - Patricia Cubi-Molla
Ispor 2019 poster - Patricia Cubi-Molla
 
Understanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to peopleUnderstanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to people
 
Novel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of lifeNovel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of life
 
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
 
HTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMRHTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMR
 
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
 
Pay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in EnglandPay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in England
 
Real option value drugs: is it really an option?
Real option value drugs: is it really an option?Real option value drugs: is it really an option?
Real option value drugs: is it really an option?
 
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
 

Recently uploaded

Doctoral Symposium at the 17th IEEE International Conference on Software Test...
Doctoral Symposium at the 17th IEEE International Conference on Software Test...Doctoral Symposium at the 17th IEEE International Conference on Software Test...
Doctoral Symposium at the 17th IEEE International Conference on Software Test...
Sebastiano Panichella
 
Sharpen existing tools or get a new toolbox? Contemporary cluster initiatives...
Sharpen existing tools or get a new toolbox? Contemporary cluster initiatives...Sharpen existing tools or get a new toolbox? Contemporary cluster initiatives...
Sharpen existing tools or get a new toolbox? Contemporary cluster initiatives...
Orkestra
 
Announcement of 18th IEEE International Conference on Software Testing, Verif...
Announcement of 18th IEEE International Conference on Software Testing, Verif...Announcement of 18th IEEE International Conference on Software Testing, Verif...
Announcement of 18th IEEE International Conference on Software Testing, Verif...
Sebastiano Panichella
 
Obesity causes and management and associated medical conditions
Obesity causes and management and associated medical conditionsObesity causes and management and associated medical conditions
Obesity causes and management and associated medical conditions
Faculty of Medicine And Health Sciences
 
International Workshop on Artificial Intelligence in Software Testing
International Workshop on Artificial Intelligence in Software TestingInternational Workshop on Artificial Intelligence in Software Testing
International Workshop on Artificial Intelligence in Software Testing
Sebastiano Panichella
 
0x01 - Newton's Third Law: Static vs. Dynamic Abusers
0x01 - Newton's Third Law:  Static vs. Dynamic Abusers0x01 - Newton's Third Law:  Static vs. Dynamic Abusers
0x01 - Newton's Third Law: Static vs. Dynamic Abusers
OWASP Beja
 
somanykidsbutsofewfathers-140705000023-phpapp02.pptx
somanykidsbutsofewfathers-140705000023-phpapp02.pptxsomanykidsbutsofewfathers-140705000023-phpapp02.pptx
somanykidsbutsofewfathers-140705000023-phpapp02.pptx
Howard Spence
 
Competition and Regulation in Professional Services – KLEINER – June 2024 OEC...
Competition and Regulation in Professional Services – KLEINER – June 2024 OEC...Competition and Regulation in Professional Services – KLEINER – June 2024 OEC...
Competition and Regulation in Professional Services – KLEINER – June 2024 OEC...
OECD Directorate for Financial and Enterprise Affairs
 
Acorn Recovery: Restore IT infra within minutes
Acorn Recovery: Restore IT infra within minutesAcorn Recovery: Restore IT infra within minutes
Acorn Recovery: Restore IT infra within minutes
IP ServerOne
 
Eureka, I found it! - Special Libraries Association 2021 Presentation
Eureka, I found it! - Special Libraries Association 2021 PresentationEureka, I found it! - Special Libraries Association 2021 Presentation
Eureka, I found it! - Special Libraries Association 2021 Presentation
Access Innovations, Inc.
 
Bonzo subscription_hjjjjjjjj5hhhhhhh_2024.pdf
Bonzo subscription_hjjjjjjjj5hhhhhhh_2024.pdfBonzo subscription_hjjjjjjjj5hhhhhhh_2024.pdf
Bonzo subscription_hjjjjjjjj5hhhhhhh_2024.pdf
khadija278284
 
Bitcoin Lightning wallet and tic-tac-toe game XOXO
Bitcoin Lightning wallet and tic-tac-toe game XOXOBitcoin Lightning wallet and tic-tac-toe game XOXO
Bitcoin Lightning wallet and tic-tac-toe game XOXO
Matjaž Lipuš
 
Getting started with Amazon Bedrock Studio and Control Tower
Getting started with Amazon Bedrock Studio and Control TowerGetting started with Amazon Bedrock Studio and Control Tower
Getting started with Amazon Bedrock Studio and Control Tower
Vladimir Samoylov
 

Recently uploaded (13)

Doctoral Symposium at the 17th IEEE International Conference on Software Test...
Doctoral Symposium at the 17th IEEE International Conference on Software Test...Doctoral Symposium at the 17th IEEE International Conference on Software Test...
Doctoral Symposium at the 17th IEEE International Conference on Software Test...
 
Sharpen existing tools or get a new toolbox? Contemporary cluster initiatives...
Sharpen existing tools or get a new toolbox? Contemporary cluster initiatives...Sharpen existing tools or get a new toolbox? Contemporary cluster initiatives...
Sharpen existing tools or get a new toolbox? Contemporary cluster initiatives...
 
Announcement of 18th IEEE International Conference on Software Testing, Verif...
Announcement of 18th IEEE International Conference on Software Testing, Verif...Announcement of 18th IEEE International Conference on Software Testing, Verif...
Announcement of 18th IEEE International Conference on Software Testing, Verif...
 
Obesity causes and management and associated medical conditions
Obesity causes and management and associated medical conditionsObesity causes and management and associated medical conditions
Obesity causes and management and associated medical conditions
 
International Workshop on Artificial Intelligence in Software Testing
International Workshop on Artificial Intelligence in Software TestingInternational Workshop on Artificial Intelligence in Software Testing
International Workshop on Artificial Intelligence in Software Testing
 
0x01 - Newton's Third Law: Static vs. Dynamic Abusers
0x01 - Newton's Third Law:  Static vs. Dynamic Abusers0x01 - Newton's Third Law:  Static vs. Dynamic Abusers
0x01 - Newton's Third Law: Static vs. Dynamic Abusers
 
somanykidsbutsofewfathers-140705000023-phpapp02.pptx
somanykidsbutsofewfathers-140705000023-phpapp02.pptxsomanykidsbutsofewfathers-140705000023-phpapp02.pptx
somanykidsbutsofewfathers-140705000023-phpapp02.pptx
 
Competition and Regulation in Professional Services – KLEINER – June 2024 OEC...
Competition and Regulation in Professional Services – KLEINER – June 2024 OEC...Competition and Regulation in Professional Services – KLEINER – June 2024 OEC...
Competition and Regulation in Professional Services – KLEINER – June 2024 OEC...
 
Acorn Recovery: Restore IT infra within minutes
Acorn Recovery: Restore IT infra within minutesAcorn Recovery: Restore IT infra within minutes
Acorn Recovery: Restore IT infra within minutes
 
Eureka, I found it! - Special Libraries Association 2021 Presentation
Eureka, I found it! - Special Libraries Association 2021 PresentationEureka, I found it! - Special Libraries Association 2021 Presentation
Eureka, I found it! - Special Libraries Association 2021 Presentation
 
Bonzo subscription_hjjjjjjjj5hhhhhhh_2024.pdf
Bonzo subscription_hjjjjjjjj5hhhhhhh_2024.pdfBonzo subscription_hjjjjjjjj5hhhhhhh_2024.pdf
Bonzo subscription_hjjjjjjjj5hhhhhhh_2024.pdf
 
Bitcoin Lightning wallet and tic-tac-toe game XOXO
Bitcoin Lightning wallet and tic-tac-toe game XOXOBitcoin Lightning wallet and tic-tac-toe game XOXO
Bitcoin Lightning wallet and tic-tac-toe game XOXO
 
Getting started with Amazon Bedrock Studio and Control Tower
Getting started with Amazon Bedrock Studio and Control TowerGetting started with Amazon Bedrock Studio and Control Tower
Getting started with Amazon Bedrock Studio and Control Tower
 

OHE at PROMs Conference Sheffield 2016: Presentations and Posters

  • 1. Do you know what you are talking about? Differences in the TTO valuation of (currently) experienced and non-experienced health profiles Cubi-Molla, Patricia1; Devlin, Nancy1; Shah, Koonal1; Herdman, Mike1 Contact: Patricia Cubi-Molla • Email: pcubi-molla@ohe.org • Tel: +44 (0)20 7747 8868 • Mobile: 07766912502 BACKGROUND Literature supports the idea that health states are usually evaluated more positively when they are experienced than when they are imagined (De Wit et al., 2000). This discrepancy is the basis of the debate about using public- or patient-based preferences. The choice of the former or the latter may lead to significantly different value sets, and it is not clear whether it is desirable for health state values to be influenced by the prior experiences of respondents Acknowledgements The authors want to thank Dr. Elly A. Stolk for her feedback on a preliminary version of the project References De Wit, G. A., Busschbach, J. J. & De Charro, F. T., 2000. Sensitivity and perspective in the valuation of health status: whose values count?. Health Economics, 9(2), pp. 109-126 Dolan, P., 1997. Modeling Valuations for EuroQol Health States. Medical Care, Volume 35, pp. 1095-1108 METHODS Nancy will be in the “experience-based” (EB) group associated to a health state H if she reported H as her own health state in [1], and H is one of the profiles she valued via TTO and VAS in [2] Koonal will be in the “non-experience-based” (NEB) group associated to H if H is one of the profiles he valued via TTO and VAS in [2], but he did not report H as his own health state in [1] Methods: (1) Probit regression models controlling for X = (sex, age, age square, if parents, if employed, and several social group and education), to analyse the characteristics of the EB group (2) ANOVA and Mean comparison (t-tests) of TTO, VAS and VAS adjusted values by group, to look for significant differences in the values between EB and NEB groups (3) Different OLS regression models to establish the effect of currently experiencing the health profile to be valued on the observed TTO value, controlling for X (4) Pearson’s or Fischer’s tests to explore differences in the ranking position of each profile with respect to death, for EB and NEB groups (5) Replicate the Dolan N3 model for generating the tariffs, but adding being in the EB group as an explanatory factor. (6) Compare EQ-VAS from "own health state" vs. raw VAS value from "hypothetical health state" (test if difference = 0) RESULTS DISCUSSION / CONCLUSION • In general, EB values for TTO and VAS seem to be slightly higher than the NEB values. However this is not observed for all the selected profiles. It is also not clear if VAS and TTO follow the same pattern, that is, if being currently experiencing a health state affects similarly the VAS and TTO valuation of it • We cannot find evidence supporting the application of different weights to the EQ-5D dimensions for creating the TTO values. • Caveat: small subsamples! • Work in progress: larger datasets (pooled across countries?) could be used to check if the results are robust to alternative definitions of the NEB group; extend the analysis to alternative definitions of “experience”. • From (1) we can suggest that the differences (if any) between the values assigned by the EB and NEB can only be attributed to the fact that the rater is currently living in the same health state as the profile she is valuing (e.g. rather than to observable characteristics of the sample) DEFINING “EXPERIENCE” Imagine we ask Nancy to value a health state H. The idea that Nancy has “experience in H” has several interpretations: i. Personal experience (“feeling”) a. Nancy is currently living in H b. Nancy lived in the past in H ii. Vicarious experience (“knowledge”) a. Affective: Nancy knows someone very closely attached to her who lived/lives in H (e.g. relative, informal carer) b. Non-affective: Nancy knows someone distant to her who lived/lives in H (e.g. health professionals, formal carers) 1 Office of Health Economics, London What we study here DATA MVH Study database (Dolan, 1997) n= 2,958 Every respondent: [1] described their own health state using the EQ-5D-3L descriptive system and EQ-VAS score [2] ranked 12 EQ-5D-3L hypothetical profiles, together with “11111”, “Unconscious” and “Immediate death”, and valued them by using: - EQ-VAS (Raw or later on Adjusted by anchoring them between “11111” and “Death”) - TTO protocol (Adjusted to [-1,1], with death = 0) AIM Explore how currently experiencing a health state H may affect the TTO or VAS valuation of H EB group NEB group Total Profile n % % Cum. n n 21111 57 22.89 22.89 1,103 1,160 11112 51 20.48 43.37 1,138 1,189 11121 51 20.48 63.85 1,132 1,183 11211 22 8.84 72.69 1,177 1,199 11122 19 7.63 80.32 711 730 12111 18 7.23 87.55 1,167 1,185 21222 14 5.62 93.17 713 727 22222 7 2.81 95.98 751 758 Other 10 4.02 100.00 27,355 27,365 Total 249 100 35,247 35,496 Other profiles (frequency): 11131 (2), 22112 (2), 33212 (2), 12211 (1), 21232 (1), 22233 (1), 32211 (1) Experience- and non-experience- based groups (1) None of the demographic and socio-economic characteristics in X has been found to be significant (at 5% level) to explain the group composition. Therefore we conclude that the EB group associated to a particular EQ profile has randomly selected among those facing the task of valuing that profile following the TTO protocol (2) Cells show the differences in means by group (mean value for experience-based minus mean value for non-experience-based). Blank cell = no evidence to reject equal means range [-1,1] [0,100] [-31.3,1] [0,100] [0,100] profile TTO VAS VAS_adj Death Full Health 21111 + 0.33* 11112 + 0.04* + 2.91* 11121 + 0.10*** + 4.17** + 0.05*** 11211 11122 + 6.00** + 0.08** - 1.24* 12111 + 0.93*** 21222 + 8.70** + 0.16*** - 4.71*** + 0.72*** 22222 + 0.38*** + 0.08* - 7.26*** n/a (3) Only significant coefficients for the dummy being in EB group or not for TTO and VAS adjusted are shown. Age and age squared are also found to be significant in most of the regressions (this is not observed in other variables in X). Additional OLS regressions have been run interacting being in EB group or not with dummies for three age categories, but the results have not changed significantly profile TTO [95% Conf. Int] VAS adjust [95% Conf. Int] 21111 -0.059** -0.117 -0.002 -0.066* -0.145 0.012 11121 0.087** 0.011 0.163 0.062* -0.010 0.133 22222 0.352** 0.008 0.695 (4) Differences are not found to be significant for the position of the selected profiles with respect to death, either for VAS or for TTO (5) The Dolan N3 regression model has been applied. The coefficient is found to be negative (-0.012) but not significant (z=-0.49). Its inclusion or running separate regressions for EB and NEB groups hardly affect the coefficients of the remaining variables (6) No evidence that both scores are significantly different or one greater than the other along all the profiles 11112 11112 22222 11122 21111 21222 11112 21111 11121 1121111121 1121112111 11122 21222 22222 21111 21111 22222 21222 21222 11211 21111 22222 11112 11122 22222 11122 21111 21111 11122 11121 21111 22222 21222 12111 12111 11121 21222 21111 11112 2111121111 21111 21222 21111 11121 21222 11122 11121 11121 21111 21111 11122 11122 21111 11121 21111 21111 11112 11112 21222 11122 21111 11211 21222 21111 12111 11112 11112 1121121222 12111 21111 22222 11211 11112 12111 11122 11121 11211 11122 21111 11211 11122 11112 11112 21111 2111111122 11121 11211 21111 11121 11211 11112 11121 21111 11121 12111 11121 11121 1121111112 11112 11112 11121 11112 11121 1112111112 11112 11112 1211111211 11121 21111 11121 11211 12111 21111 21222 11121 11112 12111 21222 11112 21111 21111 11121 11121 21111 11112 11122 11112 11121 11112 11112 21111 21111 2111111112 1112221111 2111111122 11122 11112 11112 1111211112 21111 11121 12111 11112 12111 11112 11211 11122 11121 11112 11121 11112 21111 21111 21222 11112 12111 11121 11112 1112112111 21111 11121 11112 11211 11112 11112 2111121111 11112 2111111121 11112 2111111121 12111 11112 11112 11121 21111 11211 1112121111 11211 12111 12111 21111 11121 1112111112 11121 21111 11121 21111 21111 21111 11121 21111 11112 12111 21111 11112 11121 11121 11211 21111 11112 11121 11121 11112 11121 11121 11121 11211 21111 11211 11112 11121 11211 11121 11121 11121 11112 11122 11121 0 .2.4.6.8 1 VASforself-reportedhealthprofile 0 .2 .4 .6 .8 1 VAS for hypothetical health profile Adjusted VAS values by individual in EB group 22222 21222 11122 21111 11211 12111 11112 11121 0 .2.4.6.8 1 VASforself-reportedhealthprofile 0 .2 .4 .6 .8 1 VAS for hypothetical health profile Average adjusted VAS by selected EQ profiles - EB group range [0,100] [-31.3,1] profile N VAS Corr VAS_adj Corr ALL 248 0.34 0.55 21111 57 - 5.39** 0.07 - 0.092** 0.74 11112 51 + 4.75** 0.21 + 0.067** 0.35 11121 51 0.13 0.01 11211 22 0.34 0.11 11122 19 + 6.00** 0.14 0.34 12111 18 - 5.06* -0.05 - 0.056* 0.07 21222 14 + 8.70** 0.21 0.19 22222 7 0.18 0.28